Patents Issued in February 8, 2024
  • PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS
    Publication number: 20240041842
    Abstract: The present invention relates to a pharmaceutical composition capable of effectively inhibiting the metastasis of cancer, particularly cancer in which autophagy is activated.
    Type: Application
    Filed: February 8, 2022
    Publication date: February 8, 2024
    Inventors: Hyun Seok Kim, Jang Hee HAN
  • METHODS OF TREATING CANCER
    Publication number: 20240041843
    Abstract: Provided herein are methods of treating a subject, such as a subject that has cancer, that include administering a therapeutically effective amount of a STING antagonist or a cGAS inhibitor or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having decreased ATR level and/or activity in a tumor sample obtained from the subject as compared to a reference level.
    Type: Application
    Filed: December 21, 2021
    Publication date: February 8, 2024
    Inventors: Gary Glick, Anthony William Opipari, Jr., Hans Martin Seidel
  • COMPOSITIONS AND METHODS FOR AMELIORATING HELICOBACTERACEAE INFECTIONS
    Publication number: 20240041844
    Abstract: A pharmaceutical composition includes a Helicobacteraceae enzyme inhibitor and a pharmaceutically acceptable carrier. The enzyme inhibitor may inhibit peroxiredoxin, such as alkyl hydroperoxide reductase C, thiol-specific peroxidase, bacterioferritin comigratory protein, or any combination thereof. A method for ameliorating a Helicobacteraceae infection includes administering to a subject a therapeutically effective amount of a pharmaceutical composition including a Helicobacteraceae enzyme inhibitor and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: July 20, 2023
    Publication date: February 8, 2024
    Applicant: University of Oregon
    Inventor: Arden Baylink
  • RIFABUTIN TREATMENT METHODS, USES, AND COMPOSITIONS
    Publication number: 20240041845
    Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.
    Type: Application
    Filed: October 20, 2023
    Publication date: February 8, 2024
    Inventors: Glenn E. Dale, Sergio Lociuro, Christian Kemmer, Vincent Trebosc, Marc Gitzinger
  • COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST
    Publication number: 20240041846
    Abstract: Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, compositions thereof, and methods of using them are provided.
    Type: Application
    Filed: October 12, 2023
    Publication date: February 8, 2024
    Inventors: Darrell BAKER, Mark BRUCE, Glenn CRATER, Brian NOGA, Marian THOMAS, Patrick WIRE
  • COMPOUNDS AND METHODS OF TREATING RETINAL DEGENERATION
    Publication number: 20240041847
    Abstract: A method of treating retinal degeneration in a subject includes administering to the subject a therapeutically effective amount of a compound of formula (I).
    Type: Application
    Filed: September 5, 2023
    Publication date: February 8, 2024
    Inventors: Krzysztof Palczewski, Yuanyuan Chen
  • METHODS AND COMPOSITIONS FOR TREATING HERPESVIRUS INDUCED CONDITIONS
    Publication number: 20240041848
    Abstract: Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.
    Type: Application
    Filed: June 7, 2023
    Publication date: February 8, 2024
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventor: Douglas V. FALLER
  • COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES
    Publication number: 20240041849
    Abstract: Compounds and methods are provided for the treatment of neurological or mitochondrial diseases, including epilepsy. In some embodiments, the compounds are substituted 1,4-naphthoquinones.
    Type: Application
    Filed: September 29, 2023
    Publication date: February 8, 2024
    Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: James C. CHOU, Sherine S.L. CHAN, Richard A. HIMES
  • Methods of Using Sustained Release Aminopyridine Compositions
    Publication number: 20240041850
    Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
    Type: Application
    Filed: October 9, 2023
    Publication date: February 8, 2024
    Applicant: Acorda Therapeutics, Inc.
    Inventors: Andrew R. Blight, Ron Cohen
  • METHOD OF TREATING AND PREVENTING VIRAL INFECTION
    Publication number: 20240041851
    Abstract: A method of treating and preventing viral infection in a subject comprising administering an effective amount of one or more inhibitors of folate or one-carbon metabolism pathways to the subject.
    Type: Application
    Filed: December 3, 2021
    Publication date: February 8, 2024
    Inventors: Vamsi Mootha, Benjamin Gewurz
  • METHOD FOR TREATMENT OF DISEASE CAUSED OR AGGRAVATED BY MICROORGANISMS OR RELIEVING SYMPTOMS THEREOF
    Publication number: 20240041852
    Abstract: A method for treating a disease or for treating a symptom of a disease, or a combination of both, the disease being caused or aggravated by microorganisms includes: treating the disease, treating the symptom of the disease, or reducing the duration of the disease, or a combination of both by administering a barrier-forming composition in a therapeutically effective amount to a surface, the surface comprising a mammal mucosa, the mammal being infected with the disease or experiencing symptoms of the disease caused or aggravated by the microorganisms. The barrier-forming composition includes an antimicrobial. Upon administering the composition, the method includes forming a barrier coating on the surface that is active to kill or neutralize microorganisms encountered by the barrier coating. A composition with an agent active for relieving symptoms of a disease is also included.
    Type: Application
    Filed: October 16, 2023
    Publication date: February 8, 2024
    Inventors: Afif Ghannoum, Brian Vincent Sokol
  • DOSAGE REGIMEN FOR A NR2B-NMDA RECEPTOR NAM FOR THE TREATMENT OF DEPRESSION
    Publication number: 20240041853
    Abstract: The invention relates to a dosage regimen of Compound (I), or a pharmaceutically acceptable salt thereof, for the treatment of diseases or disorders mediated by negative allosteric modulation or inhibition of NR2B-NMDA receptor including, but not limited to, major depressive disorder, treatment resistant depression and suicidality. The invention also relates to the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the treatment of major depressive disorder in patients with suicidal ideation with intent.
    Type: Application
    Filed: December 3, 2021
    Publication date: February 8, 2024
    Inventors: Jang-Ho CHA, Thomas FALLER, Baltazar GOMEZ-MANCILLA, Dimitris PAPANICOLAOU, Carman-Gabriela SERBAN, Florian VON RAISON
  • COLD MEDICINE AND ANTIVIRAL MEDICINE
    Publication number: 20240041854
    Abstract: Problem To provide a novel cold medicine or antiviral agent. Means for Solution A cold medicine comprising a compound represented by formula (1) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 30, 2021
    Publication date: February 8, 2024
    Inventors: Koushi IWATA, Kaoru IMAI
  • MODIFIED RELEASE FORMULATIONS OF PRIDOPIDINE
    Publication number: 20240041855
    Abstract: The subject invention provides a modified release solid oral dosage form comprising a therapeutically effective amount of Pridopidine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable rate controlling excipient, wherein the solid oral dosage form provides an in vivo plasma pridopidine concentration profile having a Mean Cmax of about 1,400 ng/ml or less. The subject invention also provides a method of treating an individual afflicted with a neurodegenerative disease or disease related to dopamine, comprising once daily administration of a modified release solid oral dosage form.
    Type: Application
    Filed: October 23, 2023
    Publication date: February 8, 2024
    Applicant: Prilenia Neurotherapeutics Ltd.
    Inventors: Daniella LICHT, Ioana Lovinger, Laura Yehudit Guilatt, Merav Bassan
  • LIQUID APIXABAN FORMULATION IN SMALL DOSE VOLUME
    Publication number: 20240041856
    Abstract: A pharmaceutical liquid formulation for oral delivery of apixaban comprising i) apixaban in high concentrations, ii) more than 35% (w/v) propylene glycol based on the total formulation and ii) optionally other pharmaceutical acceptable excipients, wherein the formulation is suitable for small dose volume administration. The invention relates to a liquid formulation, which can be useful as pharmaceutical formulations, for oral delivery of apixaban with a small dose volume.
    Type: Application
    Filed: December 13, 2021
    Publication date: February 8, 2024
    Inventor: Matthaios VIDALIS
  • PHARMACEUTICAL COMPOSITION FOR TREATMENT OF AORTIC ANEURYSM
    Publication number: 20240041857
    Abstract: The present invention addresses the problem of providing a therapeutic agent for abdominal aortic aneurysms, with which pharmacotherapy is possible. The present invention provides a therapeutic agent for an aortic aneurysm comprising, as an active component, (?)-6-[3-[3-cyclopropyl-3-[(1R,2R)-2-hydroxycyclohexyl]ureido]propoxy]-2(1H)-quinolinone or a salt thereof, or a solvate of these.
    Type: Application
    Filed: October 18, 2023
    Publication date: February 8, 2024
    Inventors: Naoki Unno, Hiroki Tanaka, Tatsuro Yata, Keisuke Inoue, Yuichi Makinose, Noboru Kaneta
  • ORAL FORMULATION OF A THERAPEUTIC COMPOUND
    Publication number: 20240041858
    Abstract: The present invention provides a pharmaceutical tablet formulation of tenapanor that is chemically stable and soluble comprising greater than about 6% w/w of amorphous tenapanor in its bis-HCl form, an acidifying agent, an antioxidant, a disintegrant, a lubricant, a glidant, a filler, and an immediate release coating, wherein the total chloride content of the active ingredient is greater than 5.82% and the particle diameter distribution D50 is from about from about 18 ?m to about 22 ?m.
    Type: Application
    Filed: December 6, 2021
    Publication date: February 8, 2024
    Inventors: Cecilia Gunnarsson, Magnus Swenson, Hanna Matic, John Salomonsson, Eva Karlsson
  • METHODS OF TREATING AND PREVENTING KIDNEY DISEASE
    Publication number: 20240041859
    Abstract: Among the various aspects of the present disclosure is the provision of a method of treating or preventing kidney disease in a subject in need thereof. Another aspect of the present disclosure provides for a method of reducing a number of kidney cells having excess centrosomes or centrosome amplification (CA) or inhibiting centrosome clustering in a subject having or suspected of having a kidney disease associated with CA or increased centrosome clustering. In some embodiments, the method comprises administering to the subject a centrosome clustering inhibiting agent.
    Type: Application
    Filed: December 2, 2021
    Publication date: February 8, 2024
    Applicant: Washington University
    Inventors: Mohamed 'Moe' Mahjoub, Tao Cheng
  • RESTORATION OF MOTOR FUNCTION POST-NEUROLOGICAL INJURY USING PSYCHEDELICS
    Publication number: 20240041860
    Abstract: Methods of improving motor function in subjects diagnosed with a central nervous system injury are contemplated as including an administration of a psychedelic, empathogenic, or dissociative compound in a pharmaceutically effective amount followed by administration of a motor skill restoration therapy. The psychedelic, empathogenic, or dissociative compound may be administered to a subject that has been determined to be therapy refractive with a chronic central nervous system injury, to a subject with a subacute central nervous system injury sustained within 7 days and 6 months prior, or to a subject with an acute central nervous system injury sustained within the past 7 days. Such methods may be seen improve motor function in the subjects.
    Type: Application
    Filed: December 6, 2021
    Publication date: February 8, 2024
    Inventors: Gul Dolen, John Krakauer, Romain Nardou, Steven Robert Zeiler, Junia L. De Deus
  • COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF VIRAL INFECTIONS
    Publication number: 20240041861
    Abstract: The present disclosure is directed to compositions and methods for the treatment or prevention of viral infections and diseases or conditions associated with viral infections. Among other things, the present disclosure encompasses the insight that redundant targeting of multiple pathways essential for viral infection and replication provides effective treatment and prevention of viral infection.
    Type: Application
    Filed: April 21, 2021
    Publication date: February 8, 2024
    Inventors: Rebecca Lambert Bent, Peter K. Cabeceiras
  • COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
    Publication number: 20240041862
    Abstract: This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.
    Type: Application
    Filed: October 6, 2023
    Publication date: February 8, 2024
    Inventor: Herriot Tabuteau
  • COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS
    Publication number: 20240041863
    Abstract: This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.
    Type: Application
    Filed: October 10, 2023
    Publication date: February 8, 2024
    Inventor: Herriot Tabuteau
  • METHODS FOR TREATING SOFT TISSUE SARCOMA
    Publication number: 20240041864
    Abstract: The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.
    Type: Application
    Filed: June 16, 2023
    Publication date: February 8, 2024
    Inventors: John S. KOVACH, Mickey L. WELLS
  • COMBINATION THERAPIES OF WDR-5 INHIBITORS AND PD-1 INHIBITORS
    Publication number: 20240041865
    Abstract: Provided herein are combinations that include a WDR5 inhibitor and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. Provided herein also include pharmaceutical compositions for cancer treatment, including a WDR5 inhibitor and a PD-1 inhibitor. The combinations recited herein are also useful for regulating the response of immune cells in a cancer microenvironment.
    Type: Application
    Filed: July 12, 2023
    Publication date: February 8, 2024
    Inventors: Farbod SHOJAEI, Jill M. RICONO, Mireille GILLINGS, Fairooz KABBINAVAR
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20240041866
    Abstract: A pharmaceutical composition comprising Components (1) and (2): (1) 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof; and (2) a compound having a partial structure containing two heteroatoms separated by at least two carbon atoms, or a sulfite thereof.
    Type: Application
    Filed: December 9, 2021
    Publication date: February 8, 2024
    Applicant: FUJIFILM TOYAMA CHEMICAL CO., LTD.
    Inventor: Kosuke KAKITA
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20240041867
    Abstract: A pharmaceutical composition comprising Components (1) and (2): (1) 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof; and (2) a specific amine.
    Type: Application
    Filed: December 9, 2021
    Publication date: February 8, 2024
    Applicant: FUJIFILM TOYAMA CHEMICAL CO., LTD.
    Inventor: Kosuke KAKITA
  • Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors
    Publication number: 20240041868
    Abstract: The present invention provides methods for inhibiting Fyn kinase, using 5-3-pyridin-2-amine, 6-3-imidazo[1,2-a] pyrazine, 6-3-imidazo[1,2-b] pyridazine, N-(5-imidazo [2,1-b][1,3,4] thiadiazol-2-yl)-amine, 4-3-1H-pyrazolo[3,4-b] pyridine, and N-(3-imidazo [1,2-b] pyridazin-6-yl) amine compounds and methods of treatment, prevention, inhibition or amelioration of diseases and conditions associated with Fyn kinase using such compounds.
    Type: Application
    Filed: June 2, 2023
    Publication date: February 8, 2024
    Inventor: Warren C. LAU
  • OPHTHALMIC COMPOSITION COMPRISING AN ANTI-ALLERGEN AND A REDNESS REDUCTION AGENT
    Publication number: 20240041869
    Abstract: Ophthalmic compositions comprising an anti-allergen and a redness reduction agent, such as brimonidine or a pharmaceutically acceptable salt thereof, for treating itching and redness in a single composition. The ophthalmic compositions may be provided in a container closure system, such as a low density polyethylene bottle. Container closure systems and kits comprising the ophthalmic compositions are disclosed.
    Type: Application
    Filed: August 3, 2023
    Publication date: February 8, 2024
    Applicant: Bausch + Lomb Ireland Limited
    Inventors: Zora Marlowe, Martin Coffey
  • METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS
    Publication number: 20240041870
    Abstract: The present disclosure is directed to methods for treating systemic lupus erythematosus (SLE) using the selective JAK1 inhibitor upadacitinib.
    Type: Application
    Filed: July 27, 2023
    Publication date: February 8, 2024
    Inventors: Alan W. Friedman, Mohamed-Eslam F. Mohamed
  • METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS
    Publication number: 20240041871
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Application
    Filed: October 4, 2023
    Publication date: February 8, 2024
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon MATES, Allen FIENBERG, Lawrence P. WENNOGLE
  • STABLE LURBINECTEDIN COMPOSITION
    Publication number: 20240041872
    Abstract: Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.
    Type: Application
    Filed: August 10, 2023
    Publication date: February 8, 2024
    Inventors: Pilar Calvo, Maria Tobio
  • METHOD OF TREATING SCLC AND MANAGING HEPATOTOXICITY
    Publication number: 20240041873
    Abstract: Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.
    Type: Application
    Filed: August 10, 2023
    Publication date: February 8, 2024
    Inventors: Carmen Kahatt, José María Fernandez, Salvador Fudio, Arturo Soto, Pilar Lardelli, Cristian Fernandez
  • METHOD OF TREATING SCLC AND MANAGING NEUTROPENIA
    Publication number: 20240041874
    Abstract: Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.
    Type: Application
    Filed: August 10, 2023
    Publication date: February 8, 2024
    Inventors: Carmen Kahatt, José María Fernandez, Salvador Fudio, Arturo Soto, Pilar Lardelli, Cristian Fernandez
  • METHODS OF TREATING A CORONAVIRUS INFECTION
    Publication number: 20240041875
    Abstract: Described herein, inter alia, are methods of treating a coronavirus infection.
    Type: Application
    Filed: July 28, 2023
    Publication date: February 8, 2024
    Inventors: Jianhua Yu, Michael A. Caligiuri, Lei Tian
  • PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DEGENERATIVE BRAIN DISEASES COMPRISING ABEMACICLIB AS ACTIVE INGREDIENT
    Publication number: 20240041876
    Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of degenerative brain diseases, comprising abemaciclib as an active ingredient and, in particular, to: a pharmaceutical composition for the prevention or treatment of degenerative brain diseases, comprising abemaciclib or a salt thereof as an active ingredient; and a health functional food for the prevention or amelioration of degenerative brain diseases. Abemaciclib according to the present invention has excellent activity of inhibiting an inflammatory cytokine, i.e.
    Type: Application
    Filed: August 6, 2021
    Publication date: February 8, 2024
    Inventors: Hyang Sook HOE, Hyun Ju LEE
  • DOSAGE REGIME AND METHOD FOR TREATING PULMONARY ARTERIAL HYPERTENSION
    Publication number: 20240041877
    Abstract: There is provided a daily dosage regimen for treating pulmonary arterial hypertension. The regimen takes the form of two discrete dosage forms. Each dosage form includes an amount of about 600 mg to about 800 mg of (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate. There is also another method for providing a daily dosage regimen. There is also provided several methods for treating pulmonary arterial hypertension. There is provided a method for reducing the level of serotonin biosynthesis by at least 50%. There is also provided a method for achieving an AUC0-tau of ?2530 ng·hr/mL of (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid. There is provided a method of achieving a >50% reduction in urinary 5-HIAA.
    Type: Application
    Filed: January 25, 2023
    Publication date: February 8, 2024
    Inventors: Michelle Palacios, Eric J. Gaukel, Stephen A. Wring, Magdalena Alonso-Galicia
  • APELIN RECEPTOR MODULATORS FOR TREATMENT OF A DISORDER OR DISEASE ASSOCIATED WITH BBB PERMEABILITY
    Publication number: 20240041878
    Abstract: This disclosure provides methods for using a particular class of apelin receptor modulators to reduce blood-brain barrier (BBB) permeability in a subject in need thereof, and in particular methods of treatment for a variety of disorders, conditions, and diseases associated with and related to increased BBB permeability. This disclosure also provides methods for using a particular class of apelin receptor modulators to treat a neurodegenerative disease, delirium, and/or dementia in a subject in need thereof. This disclosure also provides methods for using a particular class of apelin receptor modulators to reduce neuroinflammation in a subject in need thereof. In some embodiments, the apelin receptor modulator (e.g., agonist) is BGE-105, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 31, 2023
    Publication date: February 8, 2024
    Inventors: Justin REBO, Yan WANG, Adam LUNDQUIST, Matthew BANICKI, Robert HUGHES, Peng Khun LEONG
  • INHALABLE IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF
    Publication number: 20240041879
    Abstract: The invention relates to inhalable imatinib formulations, manufacture, and uses thereof.
    Type: Application
    Filed: October 11, 2023
    Publication date: February 8, 2024
    Inventors: Ben Dake, Ralph Niven
  • METHODS AND COMPOSITIONS TO INCREASE HAIR GROWTH AND/OR PREVENT HAIR LOSS
    Publication number: 20240041880
    Abstract: In one aspect, the disclosure relates to topical formulations, methods of making same, and methods of treating hair loss using same. In an aspect, the present disclosure pertains to topical formulations for treatment of hair loss and/or to increase hair growth, the formulation comprising: a therapeutic composition comprising therapeutically effective amounts of azelaic acid, minoxidil, finasteride, and dutasteride; and one or more compounding agents. In a further aspect, the present disclosure pertains to a method of treating hair loss by applying a disclosed topical formulation. In a further aspect, the present disclosure pertains to a method of enhancing hair grow by applying a disclosed topical formulation. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
    Type: Application
    Filed: October 11, 2023
    Publication date: February 8, 2024
    Inventors: Seymour Aaron TOMARIN, James William RICHARDS
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20240041881
    Abstract: Provided herein are methods and pharmaceutical compositions for treating cancer, in a patient in need thereof, said method comprising administering to said patient an effective amount of an EGFR inhibitor and a TNF inhibitor.
    Type: Application
    Filed: May 1, 2023
    Publication date: February 8, 2024
    Inventor: Amyn Aziz Habib
  • MINI-TABLET DOSAGE FORM OF A VIRAL TERMINASE INHIBITOR AND USES THEREOF
    Publication number: 20240041882
    Abstract: The present invention relates to oral dosage forms comprising letermovir and, in particular, to compressed mini-tablets comprising letermovir. The invention also relates to methods of using the oral dosage forms for the treatment, prevention, or prophylaxis of HCMV in a patient. In addition, the invention also provides methods for making the mini-tablets of the invention.
    Type: Application
    Filed: December 14, 2021
    Publication date: February 8, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Cory Bottone, Andrew J. Gmitter, Ashley R. Johnson, Eric A. Kemp, Feng Li, Fochive Njikam, Michael H. Wang
  • THERAPEUTIC OR PREVENTIVE AGENT FOR EYE DISEASES
    Publication number: 20240041883
    Abstract: Because 3-[(3S, 4R)-3-Methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile suppresses an increase of the retinal vascular permeability induced by VEGF, it can be used as an active ingredient of a therapeutic or preventive agent for various eye diseases involving VEGF, such as age-related macular degeneration, diabetic retinopathy, macular edema, neovascular maculopathy, retinal vein occlusion and neovascular glaucoma.
    Type: Application
    Filed: February 17, 2023
    Publication date: February 8, 2024
    Inventors: Hiromi Okigami, Tatsuji Kurose, Koushi Fujisawa, Chinami Kikkawa
  • Pharmaceutical Combinations for Treating Cancer
    Publication number: 20240041884
    Abstract: The present invention relates to pharmaceutical combinations comprising an inhibitor of an anti-apoptotic protein and a NOTCH signaling pathway inhibitor and their use in a method for the prevention, delay of progression or treatment of cancer in a subject.
    Type: Application
    Filed: December 6, 2021
    Publication date: February 8, 2024
    Inventors: Rajwinder Lehal, Charlotte Urech, Michele Vigolo
  • CELLULAR HEALTH NUTRITIONAL PRODUCT
    Publication number: 20240041885
    Abstract: A nutritional supplement composition formulated to minimize DNA damage and improve DNA repair includes Folate, Vitamin B12, Vitamin D and Zinc.
    Type: Application
    Filed: December 20, 2021
    Publication date: February 8, 2024
    Inventors: Caroline Felicity BULL, Michael FENECH, Scott William POXON, Bernardus Jan-Willem VAN KLINKEN
  • METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3
    Publication number: 20240041886
    Abstract: The present description relates to methods of treating spinocerebellar ataxia type 3 (SCA3) using substituted pyrrolo[2,3-d]pyrimidine compounds, forms, and pharmaceutical compositions thereof.
    Type: Application
    Filed: February 2, 2022
    Publication date: February 8, 2024
    Applicant: PTC Therapeutics, Inc.
    Inventors: GAYAN MIRIHANA ARACHCHILAGE, MICHAEL A. ARNOLD, SCOTT BARRAZA, ANURADHA BHATTACHARYYA, GARY MITCHELL KARP
  • COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR
    Publication number: 20240041887
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with JAK2 and/or ALK2.
    Type: Application
    Filed: July 12, 2023
    Publication date: February 8, 2024
    Inventors: Yaoyu CHEN, Matthew C. STUBBS, Ying-Nan Pan CHEN, Michelle PUSEY
  • PREVENTION AND/OR TREATMENT OF CNS DISORDERS
    Publication number: 20240041888
    Abstract: Adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including said compounds are disclosed. The present disclosure also provides methods of using said compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson's disease. The compounds and compositions may also find use in various therapeutic applications including the treatment of cancer and in immuno-oncology.
    Type: Application
    Filed: October 2, 2023
    Publication date: February 8, 2024
    Applicant: ILDONG PHARMACEUTICAL CO., LTD.
    Inventors: Kyung-Sun KIM, Jeong-Ah KIM, An-Na MOON, DONG-Keun SONG, Yoon-Suk LEE, Ju-Young JUNG
  • COMBINATION THERAPY WITH ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20240041889
    Abstract: Disclosed herein are compounds, compositions, formulations, and methods for modulating the A2B adenosine receptor in combination with immune checkpoint inhibitors in mammals with cancer.
    Type: Application
    Filed: August 6, 2021
    Publication date: February 8, 2024
    Inventors: PEIDONG FAN, LINA YAO, JIWEN LIU, ELFATIH ELZEIN
  • ANTI-HAIR-LOSS COMPOSITION
    Publication number: 20240041890
    Abstract: A composition for promoting hair growth, and/or reducing or preventing hair loss, respectively, comprises sandal pentanol, caffeine, one or more saturated and unsaturated C10-C18 fatty acids, and a solvent.
    Type: Application
    Filed: November 25, 2021
    Publication date: February 8, 2024
    Applicant: WELLA GERMANY GMBH
    Inventors: Christian Springob, Massimo Morini
  • COMPOSITIONS AND METHODS FOR IMPROVING RELAXATION, SLEEP, COGNITION, AND/OR PHYSICAL PERFORMANCE
    Publication number: 20240041891
    Abstract: The present invention comprises compositions and methods for improving relaxation, sleep, cognition, and/or physical performance. Compositions may include therapeutically effective amounts of 1,3-butanediol, in the form of R-1,3-butanediol, S-1,3-butanediol, or racemic 1,3-butanediol, in combination with a therapeutically effective amount of one or more additional active ingredients selected from caffeine, L-theanine, and a mixture of caffeine and L-theanine. Compositions may further include synergistically effective amounts of 1,3-butanediol, in the form of R-1,3-butanediol, S-1,3-butanediol, or racemic 1,3-butanediol, in combination with a synergistically effective amount of caffeine, L-theanine, or a mixture of caffeine and L-theanine.
    Type: Application
    Filed: February 2, 2022
    Publication date: February 8, 2024
    Inventors: GEOFFREY HUBERT WOO, CHRISTINE ENSLEY, LATT SHAHRIL MANSOR